PKCbeta is essential for the development of chronic lymphocytic leukemia in the TCL1 transgenic mouse model: validation of PKCbeta as a therapeutic target in chronic lymphocytic leukemia.

Holler C, PiГ±Гіn JD, Denk U, Heyder C, Hofbauer S, Greil R, Egle A. Blood. 2009 Mar 19,113(12):2791-4. doi: 10.1182/blood-2008-06-160713. Epub 2009 Jan 23.

Initial evaluation of the Roche COBAS TaqMan HIV-1 v2.0 assay for determining viral load in HIV-infected individuals.

Taylor N, Schmid I, Egle A, Greil R, Patsch W, Oberkofler H. Antivir Ther. 2009,14(8):1189-93. doi: 10.3851/IMP1427.

Circulating B-cell chronic lymphocytic leukemia cells display impaired migration to lymph nodes and bone marrow.

Hartmann TN, Grabovsky V, Wang W, Desch P, Rubenzer G, Wollner S, Binsky I, Vallon-Eberhard A, Sapoznikov A, Burger M, Shachar I, Haran M, Honczarenko M, Greil R, Alon R. Cancer Res. 2009 Apr 1,69(7):3121-30. doi: 10.1158/0008-5472.CAN-08-4136. Epub 2009 Mar 17.

Molecular and cellular mechanisms of CLL: novel therapeutic approaches.

Pleyer L, Egle A, Hartmann TN, Greil R. Nat Rev Clin Oncol. 2009 Jul,6(7):405-18. doi: 10.1038/nrclinonc.2009.72. Epub 2009 Jun 2.

Novel therapeutics approaches to chronic lymphocytic leukemia based on recent biological insights.

Hartmann TN, Pleyer L, Desch P, Egle A, Greil R. Discov Med. 2009 Oct,8(42):157-64.

The single nucleotide polymorphism MDM2-SNP309 influences sensitivity of B-CLL cells to the non-genotoxic activator of the p53 pathway Nutlin-3a

Tinhofer, I, Seyfried, I, Stoecher, M, Hofbauer, S, Daniel, PT, Greil, R J CLIN ONCOL. 2008, 26(15):

Twelve-year retrospective analysis of lung cancer-The TYROL Study: Daily routine in 1,424 patients (1995-2006)

Fiegl, M, Hilbe, W, Auberger, J, Schmid, T, Auberger, T, Tzankov, A, Sterlacci, W, Denz, H, Jamnig, H, Greil, R J CLIN ONCOL. 2008, 26(15):

MULTIPLE MYELOMA – CHEMOKINE NETWORK: CCL27/CTACK – A NEW PLAYER IN MYELOMA PROGRESSION

Olivier, A, Unger, M, Maizner, E, Neureiter, D, Greil, R, Johrer, K ANTICANCER RES. 2008, 28(5C): 3429-3429.

ZOLEDRONIC ACID (ZOL) IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (ERBC) RECEIVING ADJUVANT ENDOCRINE THERAPY: MULTIVARIATE ANALYSIS OF EFFICACY DATA FROM THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12

Gnant, M, Mlineritsch, B, Schippinger, W, Luschin-Ebengreuth, G, Steger, GG, Bjelic-Radisic, V, Jakesz, R, Kubista, E, Marth, C, Greil, R ANN ONCOL. 2008, 19: 44-44.

Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML): a proposal of the Austrian CML platform

Valent, P, Lion, T, Wolf, D, Sillaber, C, Agis, H, Petzer, A, Lang, A, Kalhs, P, Geissler, D, Greil, R, Linkesch, W, Burgstaller, S, Thaler, J, Gastl, G WIEN KLIN WOCHENSCHR. 2008, 120(21-22): 697-709.